{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:54:05Z","timestamp":1790646845948,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Comprehensive epigenomic studies in multiple myeloma (MM) that unravel the connections between major epigenetic regulators, their intertwined collaboration and the potential of combinatorial targeting remain limited. Utilizing ChIP-seq, ATAC-seq, RNA-seq, and DNA methylation (DNAme) data, we generated whole-genome chromatin annotations from normal plasma cells and MM patients, revealing epigenomic re-configuration affecting downstream genes involved in tumour growth and survival. Primary MM samples showed global DNA hypomethylation but site-specific hypermethylation was observed at transcription start sites, promoters, and enhancers. Moreover, increased deposition of H3K27me3 was observed in clinically relevant functional chromatin clusters. Combined EZH2 and DNMTs inhibition resulted in extensive epigenomic alterations activating apoptosis and cell cycle genes, leading to increased G2\/M arrest and apoptosis in MM cell lines. Our findings provide novel insights into the role of epigenetic gene silencing in MM tumorigenesis and the interplay between the Polycomb repressive complex 2 and DNAme.<\/jats:p>","DOI":"10.1038\/s41598-025-17093-z","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:49:59Z","timestamp":1756291799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation"],"prefix":"10.1038","volume":"15","author":[{"given":"Alba","family":"Atienza P\u00e1rraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nylund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klev","family":"Diamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Garrido-Zabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Iliana","family":"Tziola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louella","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Theodor","family":"Pyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroteya","family":"Raykova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Skaftason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Mart\u00edn-Subero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Komorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Jernberg Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kalushkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"17093_CR1","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando, A. G. et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche. Front. Oncol. 12, 973836 (2022).","journal-title":"Front. Oncol."},{"key":"17093_CR2","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi, J., Chen, G. & Chang, H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4, 2186\u20132207 (2013).","journal-title":"Oncotarget"},{"key":"17093_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","volume":"29","author":"MV Mateos","year":"2015","unstructured":"Mateos, M. V. et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 29, 387\u2013403 (2015).","journal-title":"Blood Rev."},{"key":"17093_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","volume":"117","author":"BA Walker","year":"2011","unstructured":"Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553\u2013562 (2011).","journal-title":"Blood"},{"key":"17093_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1101\/gr.180240.114","volume":"25","author":"X Agirre","year":"2015","unstructured":"Agirre, X. et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 25, 478\u2013487 (2015).","journal-title":"Genome Res."},{"key":"17093_CR6","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1038\/bcj.2017.27","volume":"7","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn, C. et al. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J. 7, e549 (2017).","journal-title":"Blood Cancer J."},{"key":"17093_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.clml.2019.08.010","volume":"19","author":"SR Goldsmith","year":"2019","unstructured":"Goldsmith, S. R. et al. EZH2 overexpression in multiple myeloma: prognostic value, correlation with clinical characteristics, and possible mechanisms. Clin. Lymphoma Myeloma Leuk. 19, 744\u2013750 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"17093_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1101\/gr.265520.120","volume":"30","author":"R Ordonez","year":"2020","unstructured":"Ordonez, R. et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res. 30, 1217\u20131227 (2020).","journal-title":"Genome Res."},{"key":"17093_CR9","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.7150\/thno.54453","volume":"12","author":"E Alaterre","year":"2022","unstructured":"Alaterre, E. et al. Comprehensive characterization of the epigenetic landscape in multiple myeloma. Theranostics 12, 1715\u20131729 (2022).","journal-title":"Theranostics"},{"key":"17093_CR10","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","volume":"12","author":"J Alvarez-Benayas","year":"2021","unstructured":"Alvarez-Benayas, J. et al. Chromatin-based, in Cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Nat. Commun. 12, 5450 (2021).","journal-title":"Nat. Commun."},{"key":"17093_CR11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","volume":"131","author":"Y Jin","year":"2018","unstructured":"Jin, Y. et al. Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. Blood 131, 2138\u20132150 (2018).","journal-title":"Blood"},{"key":"17093_CR12","doi-asserted-by":"publisher","first-page":"e11483","DOI":"10.1371\/journal.pone.0011483","volume":"5","author":"A Kalushkova","year":"2010","unstructured":"Kalushkova, A. et al. Polycomb target genes are silenced in multiple myeloma. PLoS One. 5, e11483 (2010).","journal-title":"PLoS One"},{"key":"17093_CR13","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.18632\/oncotarget.6843","volume":"7","author":"P Agarwal","year":"2016","unstructured":"Agarwal, P. et al. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget 7, 6809\u20136823 (2016).","journal-title":"Oncotarget"},{"key":"17093_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/cas.13840","volume":"110","author":"M Nakagawa","year":"2019","unstructured":"Nakagawa, M. et al. Dual Inhibition of enhancer of Zeste homolog 1\/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. Cancer Sci. 110, 194\u2013208 (2019).","journal-title":"Cancer Sci."},{"key":"17093_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499\u2013507 (2008).","journal-title":"Nat. Genet."},{"key":"17093_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/carcin\/bgp149","volume":"30","author":"V Bollati","year":"2009","unstructured":"Bollati, V. et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 30, 1330\u20131335 (2009).","journal-title":"Carcinogenesis"},{"key":"17093_CR17","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","volume":"6","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe, T. et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer Ther. 6, 1718\u20131727 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"17093_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas, E., Farrell, A. T., Wang, Y. C., Sridhara, R. & Pazdur, R. FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10, 176\u2013182 (2005).","journal-title":"Oncologist"},{"key":"17093_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","volume":"8","author":"W Fiskus","year":"2009","unstructured":"Fiskus, W. et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol. Ther. 8, 939\u2013950 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"17093_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ng1950","volume":"39","author":"Y Schlesinger","year":"2007","unstructured":"Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de Novo methylation in cancer. Nat. Genet. 39, 232\u2013236 (2007).","journal-title":"Nat. Genet."},{"key":"17093_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-018-0554-4","volume":"10","author":"L Herviou","year":"2018","unstructured":"Herviou, L. et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin. Epigenetics. 10, 121 (2018).","journal-title":"Clin. Epigenetics"},{"key":"17093_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1021\/cb400133j","volume":"8","author":"KD Konze","year":"2013","unstructured":"Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324\u20131334 (2013).","journal-title":"ACS Chem. Biol."},{"key":"17093_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann, C. & Lyko, F. Modes of action of the DNA methyltransferase inhibitors Azacytidine and decitabine. Int. J. Cancer. 123, 8\u201313 (2008).","journal-title":"Int. J. Cancer"},{"key":"17093_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii, S. S., Van Emburgh, B. O., Sankpal, U. T., Brown, K. D. & Robertson, K. D. DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 28, 752\u2013771 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"17093_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","volume":"21","author":"HC Tsai","year":"2012","unstructured":"Tsai, H. C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21, 430\u2013446 (2012).","journal-title":"Cancer Cell."},{"key":"17093_CR26","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1038\/nprot.2017.124","volume":"12","author":"J Ernst","year":"2017","unstructured":"Ernst, J. & Kellis, M. Chromatin-state discovery and genome annotation with chromhmm. Nat. Protoc. 12, 2478\u20132492 (2017).","journal-title":"Nat. Protoc."},{"key":"17093_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cels.2016.10.021","volume":"3","author":"JM Fernandez","year":"2016","unstructured":"Fernandez, J. M. et al. The BLUEPRINT data analysis portal. Cell. Syst. 3, 491\u2013495e495 (2016).","journal-title":"Cell. Syst."},{"key":"17093_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature09906","volume":"473","author":"J Ernst","year":"2011","unstructured":"Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43\u201349 (2011).","journal-title":"Nature"},{"key":"17093_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/nbt.3678","volume":"34","author":"J Ernst","year":"2016","unstructured":"Ernst, J. et al. Genome-scale high-resolution mapping of activating and repressive nucleotides in regulatory regions. Nat. Biotechnol. 34, 1180\u20131190 (2016).","journal-title":"Nat. Biotechnol."},{"key":"17093_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.celrep.2017.03.078","volume":"19","author":"P Fiziev","year":"2017","unstructured":"Fiziev, P. et al. Systematic epigenomic analysis reveals chromatin States associated with melanoma progression. Cell. Rep. 19, 875\u2013889 (2017).","journal-title":"Cell. Rep."},{"key":"17093_CR31","doi-asserted-by":"crossref","unstructured":"Consortium, F. et al. the, A promoter-level mammalian expression atlas. Nature ; 507: 462\u2013470. (2014).","DOI":"10.1038\/nature13182"},{"key":"17093_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41419-021-03447-8","volume":"12","author":"P Nylund","year":"2021","unstructured":"Nylund, P. et al. A distinct metabolic response characterizes sensitivity to EZH2 Inhibition in multiple myeloma. Cell. Death Dis. 12, 167 (2021).","journal-title":"Cell. Death Dis."},{"key":"17093_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3324\/haematol.2023.282965","volume":"109","author":"P Nylund","year":"2024","unstructured":"Nylund, P. et al. PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma. Haematologica 109, 567\u2013577 (2024).","journal-title":"Haematologica"},{"key":"17093_CR34","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"17093_CR35","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek, T. et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia 38, 1323\u20131333 (2024).","journal-title":"Leukemia"},{"key":"17093_CR36","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","volume":"205","author":"DM Jones","year":"2020","unstructured":"Jones, D. M., Read, K. A. & Oestreich, K. J. Dynamic roles for IL-2-STAT5 signaling in effector and regulatory CD4(+) T cell populations. J. Immunol. 205, 1721\u20131730 (2020).","journal-title":"J. Immunol."},{"key":"17093_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1182\/blood.2024024518","volume":"144","author":"D Dupere-Richer","year":"2024","unstructured":"Dupere-Richer, D. et al. KDM6A regulates immune response genes in multiple myeloma. Blood 144, 1508\u20131520 (2024).","journal-title":"Blood"},{"key":"17093_CR38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2217\/epi.15.57","volume":"7","author":"KY Wong","year":"2015","unstructured":"Wong, K. Y. & Chim, C. S. DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. Epigenomics 7, 985\u20131001 (2015).","journal-title":"Epigenomics"},{"key":"17093_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"17093_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/15680096113139990077","volume":"13","author":"V Singh","year":"2013","unstructured":"Singh, V., Sharma, P. & Capalash, N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr. Cancer Drug Targets. 13, 379\u2013399 (2013).","journal-title":"Curr. Cancer Drug Targets"},{"key":"17093_CR41","doi-asserted-by":"crossref","unstructured":"Nylund, P. et al. PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma. Haematologica (2023).","DOI":"10.3324\/haematol.2023.282965"},{"key":"17093_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire, E. et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871\u2013874 (2006).","journal-title":"Nature"},{"key":"17093_CR43","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.4049\/jimmunol.1501037","volume":"196","author":"E Coppin","year":"2016","unstructured":"Coppin, E. et al. Dok1 and Dok2 proteins regulate cell cycle in hematopoietic stem and progenitor cells. J. Immunol. 196, 4110\u20134121 (2016).","journal-title":"J. Immunol."},{"key":"17093_CR44","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1002\/jcp.26271","volume":"233","author":"PF He","year":"2018","unstructured":"He, P. F. et al. Methylation-associated DOK1 and DOK2 down-regulation: potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. J. Cell. Physiol. 233, 6604\u20136614 (2018).","journal-title":"J. Cell. Physiol."},{"key":"17093_CR45","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/leu.2010.201","volume":"24","author":"M Suljagic","year":"2010","unstructured":"Suljagic, M. et al. Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells. Leukemia 24, 2063\u20132071 (2010).","journal-title":"Leukemia"},{"key":"17093_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.thj.6200075","volume":"2","author":"R Burger","year":"2001","unstructured":"Burger, R. et al. Gp130 and Ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol. J. 2, 42\u201353 (2001).","journal-title":"Hematol. J."},{"key":"17093_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1046\/j.0007-1048.2002.03336.x","volume":"116","author":"T Otsuki","year":"2002","unstructured":"Otsuki, T. et al. Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells. Br. J. Haematol. 116, 787\u2013795 (2002).","journal-title":"Br. J. Haematol."},{"key":"17093_CR48","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1182\/blood.V73.4.1020.1020","volume":"73","author":"L Pegoraro","year":"1989","unstructured":"Pegoraro, L. et al. The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood 73, 1020\u20131027 (1989).","journal-title":"Blood"},{"key":"17093_CR49","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1182\/blood.V69.6.1605.1605","volume":"69","author":"H Jernberg","year":"1987","unstructured":"Jernberg, H. et al. Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996). Blood 69, 1605\u20131612 (1987).","journal-title":"Blood"},{"key":"17093_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"17093_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"17093_CR52","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"17093_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"17093_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/ng1547","volume":"37","author":"KL Gunderson","year":"2005","unstructured":"Gunderson, K. L., Steemers, F. J., Lee, G., Mendoza, L. G. & Chee, M. S. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37, 549\u2013554 (2005).","journal-title":"Nat. Genet."},{"key":"17093_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nmeth842","volume":"3","author":"FJ Steemers","year":"2006","unstructured":"Steemers, F. J. et al. Whole-genome genotyping with the single-base extension assay. Nat. Methods. 3, 31\u201333 (2006).","journal-title":"Nat. Methods"},{"key":"17093_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nmeth.1906","volume":"9","author":"J Ernst","year":"2012","unstructured":"Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods. 9, 215\u2013216 (2012).","journal-title":"Nat. Methods"},{"key":"17093_CR57","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ramirez","year":"2016","unstructured":"Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160\u2013165 (2016).","journal-title":"Nucleic Acids Res."},{"key":"17093_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"17093_CR59","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"17093_CR60","first-page":"e22","volume":"45","author":"W Zhou","year":"2017","unstructured":"Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and innovative use of infinium DNA methylation BeadChip probes. Nucleic Acids Res. 45, e22 (2017).","journal-title":"Nucleic Acids Res."},{"key":"17093_CR61","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1093\/bioinformatics\/btx513","volume":"33","author":"Y Tian","year":"2017","unstructured":"Tian, Y. et al. ChAMP: updated methylation analysis pipeline for illumina beadchips. Bioinformatics 33, 3982\u20133984 (2017).","journal-title":"Bioinformatics"},{"key":"17093_CR62","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan, G. et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109, 3177\u20133188 (2007).","journal-title":"Blood"},{"key":"17093_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinform. 22, 433 (2021).","journal-title":"BMC Bioinform."},{"key":"17093_CR64","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"17093_CR65","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1093\/nar\/gky545","volume":"46","author":"MP Lambert","year":"2018","unstructured":"Lambert, M. P. et al. The RNA helicase DDX17 controls the transcriptional activity of REST and the expression of proneural MicroRNAs in neuronal differentiation. Nucleic Acids Res. 46, 7686\u20137700 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17093-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:57:02Z","timestamp":1781611022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17093-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17093"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17093-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alba Atienza P\u00e1rraga is an employee of Illumina Sweden AB; Klev Diamanti is an employee of Proteomic Sciences at Thermo Fisher Scientific; Aron Skaftason is an employee of deCODE genetics, a subsidiary of Amgen and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Anqi Ma is an employee of Bristol Myers Squibb, 10300 Campus Point Dr. San Diego, CA, 92121, USA; Jian Jin is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc.; Jan Komorowski, Senior Professor of Bioinformatics, Uppsala University; Affiliate Faculty Washington National Primate Research Center, Seattle, WA, USA and Visiting Professor, Institute of Computer Science, Polish Academy of Sciences, Poland is the CEO, Methority AB, is the CEO and share-holder of Pantherai AB, a holding company for 1\/3 of Methority AB; Lucyna Komorowska, Jan Komorowski\u2019s wife, is a share-holder of Pantherai AB, a holding company for 1\/3 of Methority AB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project included no in vivo studies and ChIP-seq, ATAC-seq and RNA-seq data from primary MM and NPCs samples were provided by The Blueprint Consortium of hematopoietic epigenomes and are publicly available. DNA methylation data (Human Methylation 450k BeadChip Illumina) of primary MM and normal BMPCs was kindly provided by Dr. Mart\u00edn-Subero and is publicly available\n                      5\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"31568"}}